27
March
2014
|
00:00
Europe/Amsterdam
World’s First Pacemaker Series with Event-Triggered IEGM Transmissions Gains CE Mark
New BIOTRONIK Pacemaker Series Offers Daily Automatic Data Transmission without Relying on Patient Interaction
BERLIN, Germany, March 27, 2014—BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced CE approval for its new Eluna pacemaker series today. The new generation of pacemakers includes single and dual-chamber as well as cardiac resynchronization (CRT-P) devices. The first implantations are currently taking place worldwide, marking yet another step forward in quality for a company that has perfected the design and engineering of its products for over 50 years.With unique event-triggered IEGM transmissions, the new BIOTRONIK pacemaker series innovates advanced patient monitoring and allows physicians to receive an IEGM along with a notification if atrial fibrillation (AF) occurs. By notifying physicians of clinical events quickly and reliably, patient therapy can be adapted at the earliest stage possible, preventing the worsening of a patient’s condition and the occurrence of secondary diseases. Since nearly 25 percent of pacemaker patients suffer from AF, a type of atrial tachyarrhythmia that can be difficult to detect due to its silent nature, continuous and reliable monitoring is crucial.1 BIOTRONIK Home Monitoring® is proven to have the most reliable data transmission rates yet.2“The new BIOTRONIK pacemaker series is truly a step forward in terms of reliability and patient security,” commented Hendrik Bonnemeier, MD, of the University Clinic Schleswig-Holstein, Kiel, Germany. “Its unique ability to transmit automatic, event-triggered IEGMs really helps me deliver the best therapy, letting me know immediately if something happens to the device or patient post-implantation. The sooner I know, the sooner I can react, and that may save my patient’s life.”
About BIOTRONIK:
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.